Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab - AbbVie/AstraZeneca

Drug Profile

Adalimumab - AbbVie/AstraZeneca

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 14 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Abbott Laboratories; AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hidradenitis suppurativa; Uveitis; Pyoderma gangrenosum
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Registered Pyoderma gangrenosum
  • Discontinued Interstitial cystitis

Most Recent Events

  • 14 Oct 2021 AbbVie completes a phase III trial for Crohn's disease in Netherlands, Belgium, Norway, Finland, Portugal, Slovakia, Germany, Ireland, Denmark, France, Austria, United Kingdom, Sweden, Greece, Czech Republic, Italy and Spain (SC) (EudraCT2006-002078-23)
  • 27 Sep 2021 Launched for Ulcerative colitis (In adolescents, In children) in Japan (SC)
  • 27 Sep 2021 Preregistration for Ulcerative colitis (In adolescents, In children) in Japan (SC) prior to September 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top